Advertisement

The Action of TAAR1 Agonist RO5263397 on Executive Functions in Rats

  • Artem Dorotenko
  • Margarita Tur
  • Antonina Dolgorukova
  • Nikita Bortnikov
  • Irina V. Belozertseva
  • Edwin E. Zvartau
  • Raul R. Gainetdinov
  • Ilya SukhanovEmail author
Original Research
  • 65 Downloads

Abstract

Trace amine-associated receptor 1 (TAAR1) is a widely recognized new perspective target for the neuropsychiatric pharmacological treatment. Despite a growing number of studies investigating TAAR1 role in the animal models of different pathologies, information of TAAR1 agonists impact on executive cognitive functions is limited. The goal of the present study was to evaluate the activity of highly selective partial TAAR1 agonist RO5263397 on various executive cognitive functions. The results of the present study demonstrated that the pretreatment with RO5263397 was able to increase attention and decrease cognitive flexibility in rats. The analysis of the RO5263397 action on impulsivity demonstrated that the TAAR1 activation failed to affect premature responding but was able to slightly modify impulsive choice. Problem solving was resistant to the pharmacological intervention.

Keywords

TAAR1 RO5263397 Attention Impulsivity Cognitive flexibility Rats 

Notes

Acknowledgements

First of all, the authors would like to thank Dr Marius C. Hoener (F. Hoffmann-La Roche, Basel, Switzerland) for generous gift of compound RO5263397, Dr Mariia Dorofeikova for help in performing of OPBRS experiment, Dr Alexey I. Nevorotin, Dr Alexander Zhivich and Victor Zhivich for editing the manuscript as well as Dr Anton Bespalov for precious advices on the structure of Discussion section. The preliminary results of this study were presented at the 31st European College of Neuropsychopharmacology (ECNP) Congress (October 6–9, 2018, Barcelona, Spain) and published as the conference abstract in European Neuropsychopharmacology (2019, 29 (1S): S261–S262).

Author Contributions

IS, RRG, EEZ designed and directed the project. MT, ADor, ADol, and NB performed the experiments. IS, MT and IVB analyzed the data. All authors discussed the results and contributed to the final manuscript. IS wrote the manuscript.

Funding

This study was supported by the Russian Science Foundation (Grant #17-75-20177).

Compliance with Ethical Standards

Conflict of interest

All authors declared that they have no conflict of interest.

Ethical Approval

The First Pavlov State Saint Petersburg Medical University guideline for the care and use of animals was followed. Experimental protocols were approved by the Local Animal Care and Use Committee of First Pavlov State Saint Petersburg Medical University.

Supplementary material

10571_2019_757_MOESM1_ESM.docx (18 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. Alvarsson A, Zhang X, Stan TL et al (2015) Modulation by trace amine-associated receptor 1 of experimental parkinsonism, L-DOPA responsivity, and glutamatergic neurotransmission. J Neurosci 35:14057–14069.  https://doi.org/10.1523/JNEUROSCI.1312-15.2015 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Asif-Malik A, Hoener MC, Canales JJ (2017) Interaction between the trace amine-associated receptor 1 and the dopamine D2 receptor controls cocaine’s neurochemical actions. Sci Rep 7:13901.  https://doi.org/10.1038/s41598-017-14472-z CrossRefPubMedPubMedCentralGoogle Scholar
  3. Berry MD, Gainetdinov RR, Hoener MC, Shahid M (2017) Pharmacology of human trace amine-associated receptors: therapeutic opportunities and challenges. Pharmacol Ther 180:161–180.  https://doi.org/10.1016/j.pharmthera.2017.07.002 CrossRefPubMedGoogle Scholar
  4. Black SW, Schwartz MD, Chen T-M et al (2017) Trace amine-associated receptor 1 agonists as narcolepsy therapeutics. Biol Psychiatry 82:623–633.  https://doi.org/10.1016/j.biopsych.2016.10.012 CrossRefPubMedGoogle Scholar
  5. Borowsky B, Adham N, Jones KA et al (2001) Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci 98:8966–8971.  https://doi.org/10.1073/pnas.151105198 CrossRefPubMedGoogle Scholar
  6. Bräunig J, Dinter J, Höfig CS et al (2018) The trace amine-associated receptor 1 agonist 3-iodothyronamine induces biased signaling at the serotonin 1b receptor. Front Pharmacol 9:222.  https://doi.org/10.3389/fphar.2018.00222 CrossRefPubMedPubMedCentralGoogle Scholar
  7. Bunzow JR, Sonders MS, Arttamangkul S et al (2001) Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60:1181–1188CrossRefGoogle Scholar
  8. Cardinal RN, Robbins TW, Everitt BJ (2000) The effects of d-amphetamine, chlordiazepoxide, α-flupenthixol and behavioural manipulations on choice of signalled and unsignalled delayed reinforcement in rats. Psychopharmacology 152:362–375.  https://doi.org/10.1007/s002130000536 CrossRefPubMedGoogle Scholar
  9. Cinque S, Zoratto F, Poleggi A et al (2018) Behavioral phenotyping of dopamine transporter knockout rats: compulsive traits, motor stereotypies, and anhedonia. Front Psychiatry 9:43.  https://doi.org/10.3389/fpsyt.2018.00043 CrossRefPubMedPubMedCentralGoogle Scholar
  10. Cotter R, Pei Y, Mus L et al (2015) The trace amine-associated receptor 1 modulates methamphetamine’s neurochemical and behavioral effects. Front Neurosci 9:39.  https://doi.org/10.3389/fnins.2015.00039 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Dedic N, Jones PG, Hopkins SC et al (2019) SEP-363856, a novel psychotropic agent with a unique, non-D 2 receptor mechanism of action. J Pharmacol Exp Ther 371:1–14.  https://doi.org/10.1124/jpet.119.260281 CrossRefPubMedGoogle Scholar
  12. Di Cara B, Maggio R, Aloisi G et al (2011) Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA). J Neurosci 31:16928–16940.  https://doi.org/10.1523/JNEUROSCI.2502-11.2011 CrossRefPubMedPubMedCentralGoogle Scholar
  13. Espinoza S, Salahpour A, Masri B et al (2011) Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol 80:416–425.  https://doi.org/10.1124/mol.111.073304 CrossRefPubMedPubMedCentralGoogle Scholar
  14. Espinoza S, Ghisi V, Emanuele M et al (2015a) Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1. Neuropharmacology 93:308–313.  https://doi.org/10.1016/j.neuropharm.2015.02.010 CrossRefPubMedPubMedCentralGoogle Scholar
  15. Espinoza S, Lignani G, Caffino L et al (2015b) TAAR1 modulates cortical glutamate NMDA receptor function. Neuropsychopharmacology 40:2217–2227.  https://doi.org/10.1038/npp.2015.65 CrossRefPubMedPubMedCentralGoogle Scholar
  16. Evenden JL (1999) Varieties of impulsivity. Psychopharmacology 146:348–361.  https://doi.org/10.1007/PL00005481 CrossRefPubMedGoogle Scholar
  17. Ferragud A, Howell AD, Moore CF et al (2017) The trace amine-associated receptor 1 agonist RO5256390 blocks compulsive, binge-like eating in rats. Neuropsychopharmacology 42:1458–1470.  https://doi.org/10.1038/npp.2016.233 CrossRefPubMedGoogle Scholar
  18. Gainetdinov RR, Hoener MC, Berry MD (2018) Trace amines and their receptors. Pharmacol Rev 70:549–620.  https://doi.org/10.1124/pr.117.015305 CrossRefPubMedGoogle Scholar
  19. Goonawardena AV, Morairty SR, Dell R et al (2019) Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques. Neuropsychopharmacology.  https://doi.org/10.1038/s41386-019-0386-8 CrossRefPubMedGoogle Scholar
  20. Henderson ND (1970) Behavioral reactions of Wistar rats to conditioned fear stimuli, novelty, and noxious stimulation. J Psychol 75:19–34.  https://doi.org/10.1080/00223980.1970.9916801 CrossRefPubMedGoogle Scholar
  21. Jahn-Eimermacher A, Lasarzik I, Raber J (2011) Statistical analysis of latency outcomes in behavioral experiments. Behav Brain Res 221:271–275.  https://doi.org/10.1016/j.bbr.2011.03.007 CrossRefPubMedPubMedCentralGoogle Scholar
  22. Koblan K, Hopkins S, Justine K et al (2019) Efficacy and safety of SEP-363856, a novel psychotropic agent with a non-D2 mechanism of action, in the treatment of schizophrenia: a 4-week, randomized, placebo-controlled trial. Schizophr Bull 45:S199–S199.  https://doi.org/10.1093/schbul/sbz021.269 CrossRefGoogle Scholar
  23. Leo D, Sukhanov I, Zoratto F et al (2018) Pronounced hyperactivity, cognitive dysfunctions, and BDNF dysregulation in dopamine transporter knock-out rats. J Neurosci 38:1959–1972.  https://doi.org/10.1523/JNEUROSCI.1931-17.2018 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Lindemann L, Meyer CA, Jeanneau K et al (2008) Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324:948–956.  https://doi.org/10.1124/jpet.107.132647 CrossRefPubMedGoogle Scholar
  25. Liu J-F, Siemian JN, Seaman R et al (2017) Role of TAAR1 within the subregions of the mesocorticolimbic dopaminergic system in cocaine-seeking behavior. J Neurosci 37:882–892.  https://doi.org/10.1111/j.1471-4159.1983.tb00893.x CrossRefPubMedPubMedCentralGoogle Scholar
  26. Liu JF, Seaman R, Siemian JN et al (2018) Role of trace amine-associated receptor 1 in nicotine’s behavioral and neurochemical effects. Neuropsychopharmacology 43:2435–2444.  https://doi.org/10.1038/s41386-018-0017-9 CrossRefPubMedPubMedCentralGoogle Scholar
  27. McGaughy J, Sarter M (1995) Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands. Psychopharmacology 117:340–357CrossRefGoogle Scholar
  28. Motulsky HJ (2015) Common misconceptions about data analysis and statistics. Pharmacol Res Perspect 3:1–8.  https://doi.org/10.1002/prp2.93 CrossRefGoogle Scholar
  29. Pei Y, Mortas P, Hoener MC, Canales JJ (2015) Selective activation of the trace amine-associated receptor 1 decreases cocaine’s reinforcing efficacy and prevents cocaine-induced changes in brain reward thresholds. Prog Neuro-Psychopharmacol Biol Psychiatry 63:70–75.  https://doi.org/10.1016/j.pnpbp.2015.05.014 CrossRefGoogle Scholar
  30. Revel FG, Moreau J-L, Gainetdinov RR et al (2011) TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci 108:8485–8490.  https://doi.org/10.1073/pnas.1103029108 CrossRefPubMedGoogle Scholar
  31. Revel FG, Meyer CA, Bradaia A et al (2012a) Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine. Neuropsychopharmacology 37:2580–2592.  https://doi.org/10.1038/npp.2012.109 CrossRefPubMedPubMedCentralGoogle Scholar
  32. Revel FG, Moreau JL, Gainetdinov RR et al (2012b) Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Psychiatry 72:934–942.  https://doi.org/10.1016/j.biopsych.2012.05.014 CrossRefPubMedGoogle Scholar
  33. Revel FG, Moreau JL, Pouzet B et al (2013) A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry 18:543–556.  https://doi.org/10.1038/mp.2012.57 CrossRefPubMedGoogle Scholar
  34. Rutigliano G, Accorroni A, Zucchi R (2018) The case for TAAR1 as a modulator of central nervous system function. Front Pharmacol 8:987.  https://doi.org/10.3389/fphar.2017.00987 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Schifani C, Sukhanov I, Dorofeikova M, Bespalov A (2017) Novel reinforcement learning paradigm based on response patterning under interval schedules of reinforcement. Behav Brain Res 331:276–281.  https://doi.org/10.1016/j.bbr.2017.04.043 CrossRefPubMedGoogle Scholar
  36. Schwartz MD, Black SW, Fisher SP et al (2017) Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition. Neuropsychopharmacology 42:1305–1314.  https://doi.org/10.1038/npp.2016.216 CrossRefPubMedGoogle Scholar
  37. Sukhanov I, Zakharova ES, Danysz W, Bespalov AY (2004) Effects of NMDA receptor channel blockers, MK-801 and memantine, on locomotor activity and tolerance to delay of reward in Wistar-Kyoto and spontaneously hypertensive rats. Behav Pharmacol 15:263–271.  https://doi.org/10.1097/01.fbp.0000137212.03247.f1 CrossRefPubMedGoogle Scholar
  38. Sukhanov I, Espinoza S, Yakovlev DS et al (2014) TAAR1-dependent effects of apomorphine in mice. Int J Neuropsychopharmacol 17:1683–1693.  https://doi.org/10.1017/S1461145714000509 CrossRefPubMedGoogle Scholar
  39. Sukhanov I, Dorofeikova M, Dolgorukova A et al (2018) Trace amine-associated receptor 1 modulates the locomotor and sensitization effects of nicotine. Front Pharmacol 9:329.  https://doi.org/10.3389/fphar.2018.00329 CrossRefPubMedPubMedCentralGoogle Scholar
  40. Sukhanov I, Dorotenko A, Dolgorukova A et al (2019) Activation of trace amine-associated receptor 1 attenuates schedule-induced polydipsia in rats. Neuropharmacology.  https://doi.org/10.1016/j.neuropharm.2018.10.034 CrossRefPubMedGoogle Scholar
  41. Sukhotina IA, Dravolina OA, Novitskaya Y et al (2008) Effects of mGlu1 receptor blockade on working memory, time estimation, and impulsivity in rats. Psychopharmacology 196:211–220.  https://doi.org/10.1007/s00213-007-0953-2 CrossRefPubMedGoogle Scholar
  42. Van Gaalen MM, Unger L, Jongen-Rêlo AL et al (2009) Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors. Behav Pharmacol 20:484–491.  https://doi.org/10.1097/FBP.0b013e3283305e3b CrossRefPubMedGoogle Scholar
  43. Wolinsky TD, Swanson CJ, Smith KE et al (2007) The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6:628–639.  https://doi.org/10.1111/j.1601-183X.2006.00292.x CrossRefPubMedGoogle Scholar
  44. Xue Z, Siemian JN, Johnson BN et al (2018) Methamphetamine-induced impulsivity during chronic methamphetamine treatment in rats: effects of the TAAR 1 agonist RO5263397. Neuropharmacology 129:36–46.  https://doi.org/10.1016/j.neuropharm.2017.11.012 CrossRefPubMedGoogle Scholar
  45. Yates JR, Batten SR, Bardo MT, Beckmann JS (2015) Role of ionotropic glutamate receptors in delay and probability discounting in the rat. Psychopharmacology 232:1187–1196.  https://doi.org/10.1007/s00213-014-3747-3 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Valdman Institute of PharmacologyPavlov First St. Petersburg State Medical UniversitySt. PetersburgRussia
  2. 2.Institute of Translational BiomedicineSt. Petersburg State UniversitySt. PetersburgRussia
  3. 3.St. Petersburg University HospitalSt. Petersburg State UniversitySt. PetersburgRussia

Personalised recommendations